|
Ahlqvist-Rastad’s rating system
| | |
N
|
%
|
|---|
|
Drug for conditions with no currently available treatment
|
A
| |
0
|
0.0
|
|
Added therapeutic value*
|
B
|
B1
|
18
|
30.5
|
| |
B4
|
1
|
1.7
|
| |
Subtotal
|
19
|
32.2
|
|
Similar therapeutic value**
|
C
|
C1
|
5
|
8.5
|
| |
C2
|
20
|
33.9
|
| |
Subtotal
|
25
|
42.4
|
|
Inferior therapeutic value***
|
D
|
D1
|
2
|
3.4
|
| |
D2
|
3
|
5.1
|
| |
Subtotal
|
5
|
8.5
|
|
Uncertain therapeutic value****
|
E
| |
10
|
16.9
|
|
TOTAL
| | |
59
|
100.0
|
- *The effect (B1)/ safety (B2)/ dosage (B3)/ route of administration (B4) seems to be better for patients than that of previously licensed alternatives.
- ** First medicine of a new class of agents with similar therapeutic value to that of previously licensed alternatives (C1).
- New agent of an existing class with similar therapeutic value to that of previously licensed alternatives (C2).
- *** First medicine of a new class with inferior therapeutic value to that of previously licensed alternatives (D1).
- New agent of an existing class with inferior therapeutic value to that of previously licensed alternatives (D2).
- ****New agent whose therapeutic value remains unknown because evaluation is limited to its effects on surrogate end points.
